Back to available technologies

NO2 Mediated Generation SNO Hb

Value Proposition

Blood transfusion is the most common procedure performed in medicine. While this modality is generally administered in order to restore tissue oxygenation within a patient by increasing the number of circulating red blood cells (RBCs), transfusion with stored blood does not always achieve this effect. Paradoxically, studies have shown that transfusion with stored blood can actually increase tissue hypoxia (oxygen-deprivation), and this practice has been linked to increased morbidity and mortality. In fact, a recent systematic review of multiple studies, aimed at evaluating the effects of RBC transfusion on patient outcomes, revealed that in 42 out of 45 studies that the risk of RBC transfusion outweighed the benefits. These findings underscore the clear and urgent need for blood transfusion products that can fulfill their intended purpose.

Technology

Dr. Jonathan Stamler, a former Duke Professor and HHMI investigator, and colleagues have developed a methodology for reinvigorating blood by treating deoxygenated RBCs with an inorganic nitrite. This results in the formation of an essential variant of hemoglobin that promotes vasodilation (enhances blood flow/oxygen delivery) – a component that is markedly diminished in stored blood. Injection of nitrite-treated RBCs was shown to enhance oxygenation in swine and relieve chest pains in two senior adults without adverse effects. Thus, this invention has wide-reaching implications for various conditions/diseases that require blood transfusion (e.g. blood loss/hemorrhage), extensive tissue oxygenation (e.g. stroke, ischemia), or vasodilation (e.g. angina).

Other applications

Inhaled nitric oxide is used in the clinic for its vasodilatory effects and has been granted orphan drug status for cystic fibrosis, sarcoidosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and sickle cell vaso-occlusive crisis. Given that Dr. Stamler’s invention promotes vasodilation, nitrite-treated blood may have applicability in this domain.

Advantages

This invention is a first-of-its kind that attempts to address the limitation of vasodilation with regard to transfused blood products.

Duke File (IDF) Number

T-002190

Inventor(s)

  • Stamler, Jonathan
  • Singel, David

Patents

    • Patent Number: 8,075,922
    • Title: METHOD OF CO-INFUSING A DEOXYGENATED HEMOGLOBIN CONTAINING BLOOD SUBSTITUTE AND INORGANIC NITRITE
    • Country: United States of America

For more information please contact

College

School of Medicine (SOM)

Interested in this Technology?

Submit your interest below.